Last reviewed · How we verify

Mixtard 30:70 Novonordisk® twice daily

Hospital Universitario Central de Asturias · FDA-approved active Small molecule Quality 1/100

Mixtard 30:70 Novonordisk® twice daily is a Small molecule drug developed by Hospital Universitario Central de Asturias. It is currently FDA-approved. Also known as: Premixed 30:70 insulin two times a day.

At a glance

Generic nameMixtard 30:70 Novonordisk® twice daily
Also known asPremixed 30:70 insulin two times a day
SponsorHospital Universitario Central de Asturias
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mixtard 30:70 Novonordisk® twice daily

What is Mixtard 30:70 Novonordisk® twice daily?

Mixtard 30:70 Novonordisk® twice daily is a Small molecule drug developed by Hospital Universitario Central de Asturias.

Who makes Mixtard 30:70 Novonordisk® twice daily?

Mixtard 30:70 Novonordisk® twice daily is developed and marketed by Hospital Universitario Central de Asturias (see full Hospital Universitario Central de Asturias pipeline at /company/hospital-universitario-central-de-asturias).

Is Mixtard 30:70 Novonordisk® twice daily also known as anything else?

Mixtard 30:70 Novonordisk® twice daily is also known as Premixed 30:70 insulin two times a day.

What development phase is Mixtard 30:70 Novonordisk® twice daily in?

Mixtard 30:70 Novonordisk® twice daily is FDA-approved (marketed).

Related